RIGL Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
80.9M
+2.8%
78.7M
+33.8%
58.8M
-15.7%
69.8M
+0.5%
69.5M
Cost of Revenue
10.8M
+26.5%
8.5M
+85.1%
4.6M
-22.7%
6.0M
+25.3%
4.8M
Gross Profit
70.1M
-0.1%
70.2M
+29.5%
54.2M
-15.1%
63.8M
-1.3%
64.7M
Operating Expenses
53.0M
+13.7%
46.6M
+10.1%
42.3M
+4.1%
40.7M
+12.1%
36.3M
R&D
18.3M
+30.9%
14.0M
+19.6%
11.7M
+9.3%
10.7M
+45.3%
7.4M
SG&A
34.7M
+6.4%
32.6M
+6.5%
30.7M
+2.2%
30.0M
+3.6%
28.9M
Operating Income
17.1M
-27.4%
23.6M
+98.4%
11.9M
-48.7%
23.2M
-18.5%
28.4M
EBITDA
18.9M
-22.6%
24.4M
+95.7%
12.5M
-47.5%
23.8M
-18.1%
29.0M
Net Income
13.2M
-23.7%
17.3M
+99.8%
8.7M
-96.8%
268.1M
+860.8%
27.9M
EPS (Basic)
$0.70
-24.7%
$0.93
+97.9%
$0.47
-96.8%
$14.72
+849.7%
$1.55
EPS (Diluted)
$0.65
-26.1%
$0.88
+100.0%
$0.44
-96.7%
$13.49
+824.0%
$1.46
Shares (Diluted)
20.4M
+4.4%
19.6M
-0.6%
19.7M
-0.9%
19.9M
+3.7%
19.2M
Rigel Pharmaceuticals Inc. (New) (RIGL) — Financials